- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07432893
Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts
Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts: A Pilot Study
The goal of this clinical trial is to learn whether AI-enabled, nurse-led treatment planning can improve the quality of clinical reasoning and management compared with standard physician-led care in adult primary care patients (≥18 years) presenting with hypertension, diabetes mellitus, fever, breathlessness, or musculoskeletal pain in rural and semi-urban India.
The main questions it aims to answer are:
- Does a nurse + large language model (LLM) consultation achieve non-inferior clinical quality scores compared with a standard doctor consultation?
- Is AI-assisted nurse-led care acceptable and satisfactory to patients in primary healthcare settings? Researchers will compare nurse + LLM-led consultations with physician-led standard-of-care consultations within the same participant to see if the AI-enabled nurse model delivers comparable or improved clinical reasoning and treatment planning.
Participants will:
- Receive two sequential consultations for the same visit (one with a nurse using an AI tool and one with a physician, order randomized).
- Have both consultations audio recorded for blinded clinical quality assessment.
- Complete a brief exit survey on communication, trust, and satisfaction after the AI-assisted nurse consultation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
West Bengal
-
Birbhum, West Bengal, India
- Liver Foundation
-
Puruliya, West Bengal, India
- Liver Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged ≥18 years
- Presenting to participating primary care facilities in study sites
Meeting criteria for at least one of the following conditions or symptoms:
- Hypertension: Known diagnosis
- Diabetes mellitus: Known diagnosis or laboratory evidence (HbA1c ≥6.5%, fasting blood glucose ≥126 mg/dL, or post-prandial glucose ≥200 mg/dL)
- Fever: Presenting as chief complaint
- Breathlessness: Presenting as chief complaint, without evidence of fever
- Musculoskeletal pain: Presenting as chief complaint, without evidence of fever
- Able and willing to provide written informed consent
- Willing to participate in two sequential consultations and complete an exit survey
Exclusion Criteria:
- Inability to provide informed consent due to cognitive impairment (e.g., dementia or intellectual disability)
- Medical instability or condition requiring immediate emergency referral
- Prior participation in the study during an earlier visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nurse+Large language model clinical consultation
Participants in this arm receive a nurse-led primary care consultation supported by a large language model (LLM)-based clinical decision support tool.
During the consultation, a trained nurse conducts routine history taking and clinical assessment and engages in a multi-turn interaction with the LLM via a digital interface to support differential diagnosis, clinical reasoning, and evidence-based treatment and follow-up planning.
The nurse may ask additional questions of the patient based on LLM prompts.
The final clinical recommendations are generated collaboratively by the nurse using the LLM outputs and documented as a treatment plan.
This arm evaluates whether AI-assisted nurse-led care can deliver clinical quality comparable to standard physician-led care in primary health settings.
|
A nurse-led primary care consultation supported by a large language model-based clinical decision support tool.
The nurse uses the AI tool during the patient encounter to support clinical reasoning, differential diagnosis, and evidence-based treatment and follow-up planning.
|
|
Active Comparator: Physician led clinical consultation (standard of care)
The doctor consultation represents standard-of-care clinical management that is already known and accepted to be effective for diagnosing and treating the study conditions.
It is an active clinical intervention, not a placebo, sham, or no-intervention arm, and it serves as the comparator against the experimental nurse + LLM intervention.
|
Participants receive a routine physician-led primary care consultation conducted according to existing clinical practice.
The physician independently performs history taking, clinical assessment, diagnosis, and treatment planning without use of the AI tool.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Quality of Consultation (Clinical Management and Clinical Reasoning Score)
Time Frame: Day 1 (same study visit, immediately after completion of both consultations)
|
Clinical quality of the consultation, scored by two blinded physician graders using a domain-based rubric (Annexure 1).
Each domain is scored 0 (inadequate), 1 (suboptimal), or 2 (optimal).
Disease (clinical management: hypertension, diabetes) cases are scored on four domains - quality of history, accuracy of next steps, safety, and comprehensiveness - for a total of 0-8.
Symptom (clinical reasoning: fever, breathlessness, musculoskeletal pain) cases are scored on all six domains, adding quality of differential and accuracy of provisional diagnosis, for a total of 0-12.
The primary outcome is the absolute total score; results are also reported normalised to 0-100% for concordance with the original registration.
The two study arms (nurse+LLM vs. physician standard of care) are compared within each patient.
|
Day 1 (same study visit, immediately after completion of both consultations)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nurse-Reported Acceptability and Feasibility Themes from Semi-Structured Interviews
Time Frame: Through study completion (after nurses complete a minimum of 10 AI-assisted consultations; up to 9 months)
|
Qualitative assessment of nurse-reported usability, trust in AI recommendations, workflow impact, barriers, facilitators, and willingness to continue use.
Interviews are audio recorded and thematically analyzed.
Outcomes will be reported as identified themes with representative quotations and frequency of theme occurrence across participants.
|
Through study completion (after nurses complete a minimum of 10 AI-assisted consultations; up to 9 months)
|
|
Patient Experience on Exit Survey
Time Frame: Day 1 (immediately after completion of the nurse + LLM consultation during the study visit)
|
Patient-reported experience of the nurse+LLM consultation, measured by a brief exit survey covering three domains: communication and understanding, trust and comfort with AI use, and respect and satisfaction (one item per domain; three-point response scale).
Responses are summarised descriptively (frequencies/proportions per item and domain).
|
Day 1 (immediately after completion of the nurse + LLM consultation during the study visit)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Glucose Metabolism Disorders
- Signs and Symptoms, Respiratory
- Body Temperature Changes
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Hypertension
- Diabetes Mellitus
- Dyspnea
- Fever
Other Study ID Numbers
- HREC,IILDS/2025-R70
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.